{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:33Z","timestamp":1791068613905,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hoc.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:50:07Z","timestamp":1718956207000},"page":"1071-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-Risk Non-Melanoma Skin Cancers"],"prefix":"10.1016","volume":"38","author":[{"given":"Truelian","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib1","first-page":"110","article-title":"Non-melanoma skin cancer: statistical associations between clinical parameters","volume":"48","author":"Ciuciulete","year":"2022","journal-title":"Curr Health Sci J"},{"key":"10.1016\/j.hoc.2024.05.004_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1524-4725.2009.01236.x","article-title":"Review of the hair follicle origin hypothesis for basal cell carcinoma","volume":"35","author":"Donovan","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.hoc.2024.05.004_bib5","first-page":"3098940","article-title":"Basal cell carcinoma arises from interfollicular layer of epidermis","volume":"2018","author":"Tan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7988","key":"10.1016\/j.hoc.2024.05.004_bib6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06740-y","article-title":"The extracellular matrix dictates regional competence for tumour initiation","volume":"623","author":"Bansaccal","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2018.03.060","article-title":"Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations [published correction appears in J Am Acad Dermatol. 2021 Aug;85(2):535]","volume":"80","author":"Cameron","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biomedicines9020171","article-title":"Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Fania","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.det.2022.07.015","article-title":"Merkel Cell Carcinoma","volume":"41","author":"Lewis","year":"2023","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.004_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-016-0207-3","article-title":"Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease","volume":"17","author":"Burton","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.004_bib11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/DSS.0000000000001146","article-title":"Detection of high-risk histologic features and tumor upstaging of nonmelanoma skin cancers on debulk analysis: a quantitative systematic review","volume":"43","author":"Singh","year":"2017","journal-title":"Dermatol Surg"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.004_bib12","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/cancers14102371","article-title":"Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives","volume":"14","author":"Zambrano-Rom\u00e1n","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/humu.10179","article-title":"TP53 mutations in human skin cancers","volume":"21","author":"Giglia-Mari","year":"2003","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.004_bib14","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3390\/ijms18112485","article-title":"Understanding the molecular genetics of basal cell carcinoma","volume":"18","author":"Pellegrini","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.004_bib15","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/ijc.31724","article-title":"Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma","volume":"143","author":"Sternberg","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib16","doi-asserted-by":"crossref","first-page":"e0174565","DOI":"10.1371\/journal.pone.0174565","article-title":"GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.004_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1684\/ejd.2019.3636","article-title":"Transglutaminase 3 is expressed in basal cell carcinoma of the skin","volume":"29","author":"Smirnov","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.004_bib18","doi-asserted-by":"crossref","first-page":"eabm7981","DOI":"10.1126\/sciadv.abm7981","article-title":"Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment","volume":"8","author":"Guerrero-Juarez","year":"2022","journal-title":"Sci Adv"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.004_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-4362.1985.tb05719.x","article-title":"HLA and beta 2-microglobulin expression in basal and squamous cell carcinomas of the skin","volume":"24","author":"Hua","year":"1985","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.004_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0171-2985(11)80086-0","article-title":"HLA molecules in basal cell carcinoma of the skin","volume":"185","author":"Cabrera","year":"1992","journal-title":"Immunobiology"},{"issue":"14","key":"10.1016\/j.hoc.2024.05.004_bib21","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1158\/1078-0432.CCR-09-3136","article-title":"Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas","volume":"16","author":"Walter","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.004_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1038\/sj.jid.5700884","article-title":"Human basal cell carcinoma is associated with Foxp3+ T\u00a0cells in a Th2 dominant microenvironment","volume":"127","author":"Kaporis","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/eji.201445052","article-title":"Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer","volume":"45","author":"Nardinocchi","year":"2015","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12885-017-3663-0","article-title":"Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin [published correction appears in BMC Cancer. 2018 Jan 30;18(1):111]","volume":"17","author":"Omland","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.004_bib25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/jid.2008.310","article-title":"Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction [published correction appears in J Invest Dermatol. 2018 Feb;138(2):471]","volume":"129","author":"Tjiu","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.004_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/jdv.16098","article-title":"Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies","volume":"34","author":"Di Nardo","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41525-021-00226-4","article-title":"The landscape of driver mutations in cutaneous squamous cell carcinoma","volume":"6","author":"Chang","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/bjd.18095","article-title":"Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma","volume":"182","author":"Riihil\u00e4","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","article-title":"Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma [published correction appears in Cell. 2020 Sep 17;182(6):1661-1662]","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.004_bib31","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/jid.2012.190","article-title":"Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas","volume":"132","author":"Gehad","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2024.05.004_bib32","doi-asserted-by":"crossref","first-page":"1084873","DOI":"10.3389\/fimmu.2023.1084873","article-title":"Understanding the squamous cell carcinoma immune microenvironment","volume":"14","author":"Saeidi","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.004_bib33","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1600-0560.2007.00741.x","article-title":"Langerhans cells in squamous cell carcinoma vs. pseudoepitheliomatous hyperplasia of the skin","volume":"34","author":"Galan","year":"2007","journal-title":"J\u00a0Cutan Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.004_bib34","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/jid.2009.96","article-title":"Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation","volume":"129","author":"Bluth","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CCO.0000000000000608","article-title":"Immunobiology of Merkel cell carcinoma","volume":"32","author":"Samimi","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.chom.2016.04.024","article-title":"Identifying the target cells and mechanisms of merkel cell polyomavirus infection","volume":"19","author":"Liu","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.004_bib37","doi-asserted-by":"crossref","first-page":"101101","DOI":"10.1016\/j.xcrm.2023.101101","article-title":"Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities","volume":"4","author":"Das","year":"2023","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.004_bib38","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2010.30.6308","article-title":"Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival","volume":"29","author":"Paulson","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.004_bib39","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/jid.2013.75","article-title":"Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses","volume":"133","author":"Dowlatshahi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.004_bib40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/cells9051206","article-title":"The role of human \u03b3\u03b4 T\u00a0cells in anti-tumor immunity and their potential for cancer immunotherapy","volume":"9","author":"Liu","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hoc.2018.09.004","article-title":"Basal cell carcinoma review","volume":"33","author":"Kim","year":"2019","journal-title":"Hematol Oncol Clin N Am"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.004_bib42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.138.8.1043","article-title":"Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery","volume":"138","author":"Batra","year":"2002","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaad.2018.02.083","article-title":"Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention [published correction appears in J Am Acad Dermatol. 2019 Jul;81(1):310]","volume":"80","author":"Cameron","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib44","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14656566.2022.2050215","article-title":"Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?","volume":"23","author":"Zhu","year":"2022","journal-title":"Expet Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.004_bib47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jamadermatol.2019.1541","article-title":"Topical itraconazole for the treatment of basal cell carcinoma in patients with basal cell nevus syndrome or high-frequency basal cell carcinomas: a phase 2, open-label, placebo-controlled trial","volume":"155","author":"Sohn","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib49","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.004_bib50","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2024.05.004_bib51","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.3390\/cells11203210","article-title":"Novel approaches in non-melanoma skin cancers-a focus on hedgehog pathway in basal cell carcinoma (BCC)","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.004_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","volume":"32","author":"Lear","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib55","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2022.07.004","article-title":"Squamous cell carcinoma: an update in staging, management, and postoperative surveillance strategies","volume":"41","author":"Guzman","year":"2023","journal-title":"Dermatol Clin"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib57","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1111\/jocd.15886","article-title":"Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in\u00a0situ","volume":"22","author":"Nestor","year":"2023","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.004_bib58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ijd.12553","article-title":"Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends","volume":"54","author":"Kallini","year":"2015","journal-title":"Int J Dermatol"},{"issue":"13","key":"10.1016\/j.hoc.2024.05.004_bib59","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1245\/s10434-019-07865-z","article-title":"Sentinel Node Biopsy in 105 High-Risk Cutaneous SCCs of the Head and Neck: Results of a Multicenter Prospective Study","volume":"26","author":"Mooney","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib60","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.12788\/j.sder.2019.010","article-title":"Systemic therapy for advanced cutaneous squamous cell carcinoma","volume":"38","author":"Fitzgerald","year":"2019","journal-title":"Semin Cutan Med Surg"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.004_bib61","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/1097-0142(19910415)67:8<2030::AID-CNCR2820670803>3.0.CO;2-K","article-title":"Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin","volume":"67","author":"Khansur","year":"1991","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.hoc.2024.05.004_bib62","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.004_bib63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study","volume":"11","author":"Montaudi\u00e9","year":"2020","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.004_bib64","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for Immunotherapy-Refractory\/Ineligible Cutaneous Squamous Cell Carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.004_bib66","doi-asserted-by":"crossref","first-page":"e002757","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.004_bib67","doi-asserted-by":"crossref","first-page":"e005082","DOI":"10.1136\/jitc-2022-005082","article-title":"Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma","volume":"10","author":"Ascierto","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"26","key":"10.1016\/j.hoc.2024.05.004_bib68","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.004_bib69","doi-asserted-by":"crossref","first-page":"466.e1","DOI":"10.1016\/j.jtct.2023.01.022","article-title":"Comparison of Patient and Provider Practices between Bone Marrow and Solid Organ Transplantation Programs for Patient Education on Increased Risk of Skin Cancer","volume":"29","author":"Shope","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.004_bib70","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/TP.0000000000001644","article-title":"Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: a retrospective study of 53 cases","volume":"101","author":"Ducroux","year":"2017","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.004_bib71","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib72","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2024.05.004_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","article-title":"Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022","volume":"171","author":"Gauci","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.004_bib75","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib76","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.004_bib77","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2024.05.004_bib78","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.20.00201","article-title":"Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial","volume":"38","author":"Topalian","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2024.05.004_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-pathol-042320-120056","article-title":"Cutaneous Squamous Cell Carcinoma: The Frontier of Cancer Immunoprevention","volume":"17","author":"Chang","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.004_bib80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5021\/ad.22.042","article-title":"The Immune Microenvironment in Basal Cell Carcinoma","volume":"35","author":"Zilberg","year":"2023","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.hoc.2024.05.004_bib81","doi-asserted-by":"crossref","first-page":"216406","DOI":"10.1016\/j.canlet.2023.216406","article-title":"Skin cancer prevention - Recent advances and unmet challenges","volume":"575","author":"Mortaja","year":"2023","journal-title":"Cancer Lett"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2024.05.004_bib82","first-page":"A257","article-title":"422 An open-label, multicenter, phase 1\/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts","volume":"8","author":"Middleton","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.hoc.2024.05.004_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1474","article-title":"1089TiP Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma","volume":"32","author":"Boerlin","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib84","doi-asserted-by":"crossref","first-page":"e14558","DOI":"10.1111\/dth.14558","article-title":"Treatment of superficial basal cell carcinoma with 7.8% 5-aminolaevulinic acid nanoemulsion-based gel (BF-200 ALA) and photodynamic therapy: Results in clinical practice in a tertiary hospital","volume":"34","author":"Navarro-Trivi\u00f1o","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.hoc.2024.05.004_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpharm.2019.05.002","article-title":"Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment","volume":"565","author":"Calienni","year":"2019","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.004_bib86","doi-asserted-by":"crossref","first-page":"e125476","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.004_bib87","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"7783","key":"10.1016\/j.hoc.2024.05.004_bib88","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-019-1719-9","article-title":"Immunity to commensal papillomaviruses protects against skin cancer","volume":"575","author":"Strickley","year":"2019","journal-title":"Nature"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T16:23:25Z","timestamp":1725035005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0889858824000534"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Risk Non-Melanoma Skin Cancers","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}